COMBIVENT RESPIMAT Rx
Generic Name and Formulations:
Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free.
Boehringer Ingelheim Pharmaceuticals
Indications for COMBIVENT RESPIMAT:
COPD when a second aerosol bronchodilator is needed.
1 inh 4 times daily; max 6 inh/day.
Avoid excessive use. Discontinue if paradoxical bronchospasm occurs. Cardiovascular disorders. Arrhythmias. Hypertension. Diabetes. Hyperthyroidism. Seizure disorders. Sensitivity to sympthomimetic amines. Narrow angle glaucoma. GI or GU obstruction. Hepatic or renal disease. Pregnancy (Cat. C). Labor & delivery. Nursing mothers: not recommended.
Extreme caution within 2 weeks of MAOIs or tricyclic antidepressants (increased cardiovascular effects). Caution with other anticholinergics, sympathomimetics, drugs that lower serum potassium. Antagonized by beta-blockers.
Anticholinergic + beta-2 agonist.
Upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, dyspnea; paradoxical bronchospasm, urinary retention, hypokalemia, hypersensitivity reactions, ocular effects.
Ipratropium bromide: renal.
Inhaler—4g (120 inh)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders